1. Home
  2. GNLN vs HEPA Comparison

GNLN vs HEPA Comparison

Compare GNLN & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNLN
  • HEPA
  • Stock Information
  • Founded
  • GNLN 2005
  • HEPA 2013
  • Country
  • GNLN United States
  • HEPA United States
  • Employees
  • GNLN N/A
  • HEPA N/A
  • Industry
  • GNLN Durable Goods
  • HEPA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNLN Consumer Discretionary
  • HEPA Health Care
  • Exchange
  • GNLN Nasdaq
  • HEPA Nasdaq
  • Market Cap
  • GNLN 1.6M
  • HEPA 1.7M
  • IPO Year
  • GNLN 2019
  • HEPA N/A
  • Fundamental
  • Price
  • GNLN $0.74
  • HEPA $0.17
  • Analyst Decision
  • GNLN
  • HEPA
  • Analyst Count
  • GNLN 0
  • HEPA 0
  • Target Price
  • GNLN N/A
  • HEPA N/A
  • AVG Volume (30 Days)
  • GNLN 279.5K
  • HEPA 31.4M
  • Earning Date
  • GNLN 11-15-2024
  • HEPA 04-15-2025
  • Dividend Yield
  • GNLN N/A
  • HEPA N/A
  • EPS Growth
  • GNLN N/A
  • HEPA N/A
  • EPS
  • GNLN N/A
  • HEPA N/A
  • Revenue
  • GNLN $21,605,000.00
  • HEPA N/A
  • Revenue This Year
  • GNLN $72.27
  • HEPA N/A
  • Revenue Next Year
  • GNLN $93.46
  • HEPA N/A
  • P/E Ratio
  • GNLN N/A
  • HEPA N/A
  • Revenue Growth
  • GNLN N/A
  • HEPA N/A
  • 52 Week Low
  • GNLN $0.70
  • HEPA $0.12
  • 52 Week High
  • GNLN $21.80
  • HEPA $3.33
  • Technical
  • Relative Strength Index (RSI)
  • GNLN 18.97
  • HEPA 36.41
  • Support Level
  • GNLN $0.70
  • HEPA $0.17
  • Resistance Level
  • GNLN $1.60
  • HEPA $0.19
  • Average True Range (ATR)
  • GNLN 0.12
  • HEPA 0.02
  • MACD
  • GNLN -0.06
  • HEPA 0.01
  • Stochastic Oscillator
  • GNLN 4.34
  • HEPA 28.55

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a distributor of vaporization products and consumption accessories in the United States. It offers a selection of stock-keeping units including vaporizers and parts, cleaning products, grinders and storage containers, pipes, rolling papers and customized lines of premium specialty packaging. The company markets and sells its products in both the business to business and business to consumer sectors of the marketplace. Its geographical segment includes the United States; Canada and Europe. It derives a majority of revenue from the United States.

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Share on Social Networks: